Capivasertib plus abiraterone and ADT improved rPFS in PTEN-deficient metastatic hormone-sensitive prostate cancer.

Around 3,000 women a year with advanced cancer could benefit from capivasertib which can slow the disease.

Around 3,000 women a year with advanced cancer could benefit from capivasertib which can slow the disease.

Around 3,000 women a year with advanced cancer could benefit from capivasertib which can slow the disease.

Gwen Buchan, 62, says capivasertib will allow her to see her son's wedding and offers her "hope".

YouTube video by Dr Liz O'Riordan

Rana McKay: CAPItello-281 phase 3 in PTEN-deficient Metastatic Hormone-Sensitive Prostate Cancer / abiraterone, cancer, CAPItello-281, Capivasertib, fight

AKT pathway activation is implicated in endocrine-therapy resistance. Data on the efficacy and safety of the AKT inhibitor capivasertib, as an addition to fulvestrant therapy, in patients with horm...

The U.S. Food and Drug Administration (FDA) has approved capivasertib (Truqap) in combination with abiraterone and prednisone for adults with metastatic hormone-sensitive prostate cancer that has a PT

U-turn by medicines watchdog means about 3,000 women with advanced forms of disease could benefit each year Thousands of women with advanced breast cancer in England and Wales are to be offered a “gamechanging” twice-a-day pill on the NHS after a U-turn by the medicines watchdog. Experts hailed the decision as a “landmark moment”. As many as 3,000 women every year could benefit from capivasertib for hormone receptor (HR)-positive HER2-negative breast cancer that has certain genetic mutations and has spread. Continue reading...

Around 3,000 women a year with advanced cancer could benefit from capivasertib which can slow the disease.

Melanie Sturtevant, associate director of policy, evidence and influencing at Breast Cancer Now, said:

Menarini Group has announced promising early results from the ELEVATE study evaluating elacestrant with capivasertib for ER+, HER2- metastatic breast cancer, showcased at ASCO 2026.

Around 3,000 women a year with advanced cancer could benefit from capivasertib which can slow the disease.

Menarini Group presents exciting preliminary data on the efficacy and safety of Elacestrant combined with Capivasertib for ER+/HER2- metastatic breast cancer at ASCO 2026.

Around 3,000 women a year with advanced cancer could benefit from capivasertib which can slow the disease.

Menarini Group provides new insights into the ELEVATE study, showcasing the potential of elacestrant and capivasertib for treating ER+, HER2- metastatic breast cancer. Key findings will be showcased at ASCO 2026.

Capivasertib plus abiraterone combination lands indication for PTEN-deficient tumors